Sonova Holding (OTCMKTS:SONVY) Given Average Rating of “Hold” by Brokerages

Shares of Sonova Holding (OTCMKTS:SONVY) have earned an average rating of “Hold” from the nine research firms that are presently covering the firm, MarketBeat reports. Three research analysts have rated the stock with a sell recommendation, four have given a hold recommendation, one has given a buy recommendation and one has given a strong buy recommendation to the company.

A number of brokerages have recently commented on SONVY. Zacks Research lowered Sonova from a “hold” rating to a “strong sell” rating in a report on Tuesday, December 9th. Royal Bank Of Canada raised shares of Sonova to a “moderate buy” rating in a research report on Tuesday, November 18th. BNP Paribas Exane began coverage on shares of Sonova in a report on Monday, October 20th. They issued an “underperform” rating for the company. Finally, Rothschild Redb upgraded shares of Sonova from a “strong sell” rating to a “hold” rating in a research report on Monday, October 6th.

Sonova Stock Performance

OTCMKTS SONVY opened at $54.89 on Thursday. The stock has a 50-day simple moving average of $52.07 and a 200 day simple moving average of $54.78. Sonova has a twelve month low of $47.55 and a twelve month high of $71.50. The company has a debt-to-equity ratio of 0.51, a current ratio of 1.24 and a quick ratio of 0.91.

Sonova Company Profile

Sonova AG (OTCMKTS:SONVY) is a Switzerland-based provider of hearing care solutions, headquartered in Stäfa. The company designs, develops, manufactures and distributes a range of audiological products and related services aimed at improving hearing and communication for people with hearing loss. Its portfolio spans behind-the-ear and in-the-ear hearing instruments, wireless accessories and software solutions that enable connectivity with consumer devices and audiological fittings.

Sonova markets its products under several well-known brands, including Phonak and Unitron for hearing aids, and it is also associated with Advanced Bionics for cochlear implant systems.